JP7149273B2 - Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 - Google Patents

Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 Download PDF

Info

Publication number
JP7149273B2
JP7149273B2 JP2019533166A JP2019533166A JP7149273B2 JP 7149273 B2 JP7149273 B2 JP 7149273B2 JP 2019533166 A JP2019533166 A JP 2019533166A JP 2019533166 A JP2019533166 A JP 2019533166A JP 7149273 B2 JP7149273 B2 JP 7149273B2
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
cell
transcription factor
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511115A5 (enExample
JP2020511115A (ja
Inventor
マーティン プーレ，
サイモン トーマス，
ショーン コルドバ，
ウェン チェアン リム，
Original Assignee
オートラス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オートラス リミテッド filed Critical オートラス リミテッド
Publication of JP2020511115A publication Critical patent/JP2020511115A/ja
Publication of JP2020511115A5 publication Critical patent/JP2020511115A5/ja
Priority to JP2022126972A priority Critical patent/JP2022145846A/ja
Application granted granted Critical
Publication of JP7149273B2 publication Critical patent/JP7149273B2/ja
Priority to JP2024114672A priority patent/JP2024133286A/ja
Priority to JP2024114673A priority patent/JP7874133B2/ja
Priority to JP2026062594A priority patent/JP2026095705A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019533166A 2016-12-21 2017-12-20 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 Active JP7149273B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022126972A JP2022145846A (ja) 2016-12-21 2022-08-09 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024114672A JP2024133286A (ja) 2016-12-21 2024-07-18 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024114673A JP7874133B2 (ja) 2016-12-21 2024-07-18 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2026062594A JP2026095705A (ja) 2016-12-21 2026-04-06 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1621889.3 2016-12-21
GBGB1621889.3A GB201621889D0 (en) 2016-12-21 2016-12-21 Cell
PCT/GB2017/053834 WO2018115865A1 (en) 2016-12-21 2017-12-20 Cell expressing a car and a transcription factor and its use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022126972A Division JP2022145846A (ja) 2016-12-21 2022-08-09 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用

Publications (3)

Publication Number Publication Date
JP2020511115A JP2020511115A (ja) 2020-04-16
JP2020511115A5 JP2020511115A5 (enExample) 2020-12-03
JP7149273B2 true JP7149273B2 (ja) 2022-10-06

Family

ID=58284380

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019533166A Active JP7149273B2 (ja) 2016-12-21 2017-12-20 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2022126972A Withdrawn JP2022145846A (ja) 2016-12-21 2022-08-09 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024114672A Pending JP2024133286A (ja) 2016-12-21 2024-07-18 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024114673A Active JP7874133B2 (ja) 2016-12-21 2024-07-18 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2026062594A Pending JP2026095705A (ja) 2016-12-21 2026-04-06 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022126972A Withdrawn JP2022145846A (ja) 2016-12-21 2022-08-09 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024114672A Pending JP2024133286A (ja) 2016-12-21 2024-07-18 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024114673A Active JP7874133B2 (ja) 2016-12-21 2024-07-18 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2026062594A Pending JP2026095705A (ja) 2016-12-21 2026-04-06 Ｃａｒおよび転写因子を発現する細胞、ならびにその使用

Country Status (8)

Country Link
US (2) US20200030379A1 (enExample)
EP (1) EP3559213A1 (enExample)
JP (5) JP7149273B2 (enExample)
CN (1) CN110099997A (enExample)
AU (1) AU2017380449B2 (enExample)
CA (1) CA3047621C (enExample)
GB (1) GB201621889D0 (enExample)
WO (1) WO2018115865A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220127570A1 (en) 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
US20210363217A1 (en) * 2018-06-19 2021-11-25 Autolus Limited Cell
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2022103789A1 (en) 2020-11-10 2022-05-19 Kyverna Therapeutics, Inc. A method for treating disease using foxp3+cd4+ t cells
CN114805596B (zh) * 2021-01-22 2023-07-14 华东师范大学 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用
WO2022164959A1 (en) 2021-01-27 2022-08-04 Lyell Immunopharma, Inc. Improved immune cell therapy
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
TW202246511A (zh) 2021-02-25 2022-12-01 美商萊爾免疫藥物股份有限公司 靶向ny-eso-1之增強免疫細胞療法
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
US20230313138A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
EP4514363A4 (en) * 2022-04-25 2026-04-22 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR PREVENTING T LYMPHOCYTE DEPLETION
US20260083846A1 (en) 2022-05-19 2026-03-26 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525881A (ja) 2013-05-14 2016-09-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016193696A1 (en) 2015-06-01 2016-12-08 Ucl Business Plc Cell

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098283B2 (en) * 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525881A (ja) 2013-05-14 2016-09-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016193696A1 (en) 2015-06-01 2016-12-08 Ucl Business Plc Cell

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ichii, H. et.al.，Bcl6 acts as an amplifier for the generation and proliferative capacity of central memory CD8+ T cells，The Journal of Immunology，2004年，Vol.173，pp.883-891
Roychoudhuri, R. et.al.，BACH2 regulates CD8+ T cell differentiation by cotrolling access of AP-1 factors to enhancers，Nature Immunology，2016年11月09日，Vol.17, No.7，pp.851-860
Shin. H. et.al.，A role for the transcriptional repressor Blimp-1 in CD8+ T cell exhaustion during chronic viral infection，Immunity，2009年，Vol.31，pp.309-320

Also Published As

Publication number Publication date
JP2024133287A (ja) 2024-10-01
US20200030379A1 (en) 2020-01-30
EP3559213A1 (en) 2019-10-30
JP2024133286A (ja) 2024-10-01
JP7874133B2 (ja) 2026-06-15
JP2020511115A (ja) 2020-04-16
CA3047621C (en) 2024-01-02
GB201621889D0 (en) 2017-02-01
JP2026095705A (ja) 2026-06-11
AU2017380449B2 (en) 2023-01-05
WO2018115865A1 (en) 2018-06-28
AU2017380449A1 (en) 2019-06-13
CN110099997A (zh) 2019-08-06
CA3047621A1 (en) 2018-06-28
US20240307440A1 (en) 2024-09-19
JP2022145846A (ja) 2022-10-04

Similar Documents

Publication Publication Date Title
JP2022145846A (ja) Ｃａｒおよび転写因子を発現する細胞、ならびにその使用
JP2024024014A (ja) 受容体
CN108026151B (zh) Pd-1-cd28融合蛋白及其在医学中的用途
EP3681995B1 (en) Cell
JP7117304B2 (ja) 転写システム
CA3111384A1 (en) Allogeneic cell compositions and methods of use
KR20250058773A (ko) 키메라 항원 수용체 및 이의 용도
CN118852462A (zh) 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
JP2023076572A (ja) キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
JP2020537521A (ja) 細胞
CN113195527A (zh) Tcr和肽
EP3303568A1 (en) Cell
KR20210013691A (ko) 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도
JP2024519614A (ja) Ｐｒａｍｅ特異的ｔ細胞受容体とキメラ補助刺激受容体との組合せ
JP2024036532A (ja) 操作された細胞溶解性免疫細胞
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
JP2024531430A (ja) 抗原特異的ｔ細胞受容体とキメラ補助刺激受容体との組合せ
WO2025125363A1 (en) Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220926

R150 Certificate of patent or registration of utility model

Ref document number: 7149273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250